In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys
XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland.
UTIPRO® PLUS AF, in its composition free from ingredients of animal origin, has been recently launched in the Republic of Ireland, thus further enlarging its presence across Europe. The product is distributed by Pamex, an Irish company specialized in the detailing and the distribution of high quality and innovative products, mainly addressed to female health and care. Pamex, through its sales force made of 9 dedicated REPS, will introduce the product across Primary, Secondary, Pharmacy & Specialized Care.
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.
